TABLE 2.
Incidence of adverse effects in patients treated with sorafenib
|
Sorafenib dose/day
|
P | ||
|---|---|---|---|
| 800 mg (n=33) | 400 mg (n=66) | ||
| Overall | 31 (94) | 51 (77) | 0.04 |
| Dermatological | 16 (48) | 21 (32) | 0.12 |
| Rash | 6 (18) | 11 (17) | 1.00 |
| Hand-foot syndrome | 10 (30) | 10 (15) | 0.11 |
| Constitutional | 13 (40) | 15 (23) | 0.10 |
| Fatigue | 13 (40) | 15 (23) | 0.10 |
| Weight loss | 5 (5) | 8 (12) | 0.75 |
| Gastrointestinal | 9 (27) | 20 (31) | 0.80 |
| Nausea/vomiting | 4 (12) | 9 (14) | 1.00 |
| Diarrhea | 7 (21) | 11 (17) | 0.59 |
| Elevated liver function tests | 2 (6) | 7 (11) | 0.71 |
| Hypertension | 2 (6) | 7 (11) | 0.70 |
| Gastrointestinal bleed | 1 (3) | 2 (3) | 1.00 |
| Other | 6 (18) | 14 (21) | 0.80 |
Data presented as n (%) unless otherwise indicated. Bolded value indicates statistical significance